UNSPSC 51142554: Lisuride maleate

This classification denotes an antiparkinsonian agent with the molecular formula C20H26N4O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UV1635N8XW, chemically known as 3-(9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea but more generally known as lisuride maleate, which bears US NIH Compound Identifier 28864. European Medicines Agency schedules Lisuride maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02940MIG.

Most nations, for tariff and trade purposes, schedule lisuride maleate under HS 29396900 and SITC 54146. As of Q4 2014, LISURIDE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3C[NH]C4C3C(CCC4)C2=C1)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51142554 Lisuride maleate, a Commodity code, does not align with recent state and local procurement activity. The three most recent opportunities tagged under this code involve naloxone and drug deactivation systems, a Therapeutic Pharmacy Initiative for direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing—none of which involve lisuride maleate, a dopamine agonist used in treating Parkinson's disease. The mismatch suggests that lisuride maleate sees little to no current state and local solicitation activity, or that issuing bodies have incorrectly applied the code to tangentially related pharmaceutical categories.

The actual procurement activity appearing under this code encompasses much broader pharmaceutical distribution and benefit management. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission posted an RFI in April 2026 to explore direct-to-manufacturer prescription program capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with proposals due March 26, 2026 and awards effective July 1, 2026. The code's recent activity reflects state health agencies, county public health departments, and cooperative purchasing organizations focused on broad pharmaceutical supply chains rather than a single active pharmaceutical ingredient.